H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Veru Inc (NASDAQ: VERU) today and set a price target of $5. The company’s shares closed yesterday at $2.03.
Selvaraju commented:
“Valuation methodology. Our price target is derived from a market value of the firm at $302M, which includes a discounted cash flow-based asset value of $313M for DRS, excluding $10.7M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS. Risks include, but are not limited to: (1) failure of FC2 or Tamsulosin DRS to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of Tamsulosin DRS in clinical trials; (3) clinical trial failures with other pipeline candidates; and (4) potential dilution risk.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.9% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Veru Inc has an analyst consensus of Moderate Buy, with a price target consensus of $7.50, a 269.5% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
Based on Veru Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.93 million. In comparison, last year the company had a GAAP net loss of $789.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture, and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.
